Compare LASE & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASE | INO |
|---|---|---|
| Founded | 2019 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.7M | 90.5M |
| IPO Year | 2021 | 1999 |
| Metric | LASE | INO |
|---|---|---|
| Price | $2.74 | $1.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | ★ 30.9M | 1.8M |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | N/A | ★ N/A |
| Revenue | $721,185.00 | ★ $42,220,086.00 |
| Revenue This Year | N/A | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $0.38 | $1.03 |
| 52 Week High | $6.77 | $2.86 |
| Indicator | LASE | INO |
|---|---|---|
| Relative Strength Index (RSI) | 61.42 | 41.69 |
| Support Level | $1.90 | $1.03 |
| Resistance Level | $3.06 | $1.23 |
| Average True Range (ATR) | 0.70 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 50.02 | 18.33 |
Laser Photonics Corp is an integrated manufacturing company for photonics-based industrial products and solutions, laser cleaning technologies. Its laser-blasting technologies are focused on disrupting the sandblasting and abrasive blasting markets. The company offers a portfolio of integrated laser-blasting solutions for corrosion control, rust removal, de-coating, pre-welding and post-welding, laser cleaning, and surface conditioning. Its laser-blasting solutions are applicable in every industry dealing with materials processing, including automotive, aerospace, healthcare, consumer products, shipbuilding, machine manufacturing, nuclear maintenance and decommissioning, and surface coating. Geographically, the company generates almost all of its revenue from the domestic market.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.